Do drug transporter (ABCB1) SNPs influence cyclosporine and tacrolimus dose requirements and renal allograft outcome in the posttransplantation period?

Journal of Clinical Pharmacology

Volumn 51, Issue 4, 2011, Pages 603-615

  Singh, Ranjana ^a   Srivastava, Aneesh ^a   Kapoor, Rakesh ^a   Mittal, Rama Devi ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

ABCB1; Allograft outcome; Cyclosporine A; Gene polymorphism; Renal transplantation; Tacrolimus

Indexed keywords

CLARITHROMYCIN; CYCLOSPORIN A; DILTIAZEM; ERYTHROMYCIN; FLUCONAZOLE; METHYLPREDNISOLONE; MULTIDRUG RESISTANCE PROTEIN 1; PANGRAF; PHENYTOIN; PREDNISOLONE; TACROLIMUS; UNCLASSIFIED DRUG; VERAPAMIL;

ADULT; ARTICLE; DRUG BLOOD LEVEL; FEMALE; GENOTYPE; GRAFT REJECTION; HAPLOTYPE; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRAFT REJECTION; HAPLOTYPES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; TACROLIMUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 79953801622     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010370704     Document Type: Article

References (29)

1. Kahan BD, Welsh M, Schoenberg L, et al. Variable oral absorption of cyclosporine: a biopharmaceutical risk factor for chronic renal allograft rejection. Transplantation. 1996;62:599-606. (Pubitemid 26313901)
2. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 a (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004;75:13-33. (Pubitemid 38130115)
3. Coon JS, Wang YZ, Bines SD, Markham PN, Chong AS, Gebel HM. Multidrug resistance activity in human lymphocytes. Hum Immunol. 1991;32:134-140.
4. Chaudhary PM, Mechetner EB, Roninson IB. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood. 1992;80:2735-2739.
5. Vergara E, Gomez-Morales M, Ramirez C, et al. P-glycoprotein expression in acute kidney graft rejection. Transplant Proc. 1998;30:2425-2426. (Pubitemid 28399560)
6. Melk A, Daniel V, Weimer R, et al. P-glycoprotein expression is not a useful predictor of acute or chronic kidney graft rejection. Transplant Int. 1999;12:10-17. (Pubitemid 29134500)
7. Barnard JB, Richardson S, Sheldon S, et al. The MDR1/ABCB1 gene, a high-impact risk factor for cardiac transplant rejection. Transplantation. 2006;82:1677-1682. (Pubitemid 46035651)
8. Sakaeda T, Nakamura T, Okumura K. Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics. 2003;4:397-410. (Pubitemid 36857176)
9. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA. 2000;97:3473-3478. (Pubitemid 30183327)
10. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int. 1999;55:713-723. (Pubitemid 29082898)
11. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.
12. Furuno T, Landi MT, Ceroni M, et al. Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics. 2002;12:529-534. (Pubitemid 35177082)
13. Huang M, Chen Y, Chang C, Huang Y, Huang C. Polymorphisms of the gene encoding multidrug resistance protein 1 in Taiwanese. J Food Drug Anal. 2005;13:112-117.
14. Haufroid V, Mourad M, Van Kerckhove V, et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics. 2004;14:147-154. (Pubitemid 38373108)
15. Cascorbi I, Gerloff T, Johne A, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther. 2001;69:169-174. (Pubitemid 32225417)
16. Hamdy SI, Hiratsuka M, Narahara K, et al. Genotype and allele frequencies of TPMT, NAT2, GST, SULT1A1 and MDR-1 in the Egyptian population. Br J Clin Pharmacol. 2003;55:560-569. (Pubitemid 36783197)
17. Singh R, Kesarwani P, Srivastava A, Mittal RD. ABCB1 G2677 allele is associated with high dose requirement of cyclosporin A to prevent renal allograft rejection in North India. Arch Med Res. 2008;39:695-701.
18. von Ahsen N, Richter M, Grupp C, Ringe B, Oellerich M, Armstrong VW. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem. 2001;47:1048-1052. (Pubitemid 32493590)
19. Goto M, Masuda S, Saito H, et al. C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics. 2002;12:451-457. (Pubitemid 34913527)
20. Armendáriz Y, García S, Lopez RM, Pou L. Hematocrit influences immunoassay performance for the measurement of tacrolimus in whole blood. Ther Drug Monit. 2005;27:766-769. (Pubitemid 44391732)
21. Anglicheau D, Verstuyft C, Laurent-Puig P, et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol. 2003;14:1889-1896. (Pubitemid 36750485)
22. Elens L, Capron A, Kerckhove VV, et al. 1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation. Pharmacogenet Genomics. 2007;17:873-883. (Pubitemid 47462301)
23. Mai I, Störmer E, Goldammer M, et al. MDR1 haplotypes do not affect the steady-state pharmacokinetics of cyclosporine in renal transplant patients. J Clin Pharmacol. 2003;43:1101-1107. (Pubitemid 37174441)
24. Bandur S, Petrasek J, Hribova P, Novotna E, Brabcova I, Viklicky O. Haplotypic structure of ABCB1/MDR1 gene modifies the risk of the acute allograft rejection in renal transplant recipients. Transplantation. 2008;86:1206-1213.
25. Fakata KL, Elmquist WF, Swanson SA, Vorce RL, Prince C, Stemmer PM. Cyclosporin A has low potency as a calcineurin inhibitor in cells expressing high levels of P-glycoprotein. Life Sci. 1998;62:2441-2448. (Pubitemid 28273151)
26. Singh D, Alexander J, Owen A, et al. Whole-blood cultures from renal-transplant patients stimulated ex vivo show that the effects of cyclosporine on lymphocyte proliferation are related to P-glycoprotein expression. Transplantation. 2004;77:557-561. (Pubitemid 38282812)
27. Cattaneo D, Ruggenenti P, Baldelli S, et al; Mycophenolate Steroids Sparing (MYSS) Genetics Study Group. ABCB1 genotypes predict cyclosporine-related adverse events and kidney allograft outcome. J Am Soc Nephrol. 2009;20:1404-1415.
28. An P, Wang LH, Hutcheson-Dilks H, et al. Regulatory polymorphisms in the cyclophilin A gene, PPIA, accelerate progression to AIDS. PLoS Pathog. 2007;3:e88.
29. Rits MA, van Dort KA, Kootstra NA. Polymorphisms in the regulatory region of the cyclophilin A gene influence the susceptibility for HIV-1 infection. PLoS One. 2008;3:e3975.